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Abstract
Introduction: In addition to being a risk factor for breast cancer, breast density has been hypothesized to be a
surrogate biomarker for predicting response to endocrine-based chemotherapies. The purpose of this study was to
evaluate whether a noninvasive bedside scanner based on diffuse optical spectroscopic imaging (DOSI) provides
quantitative metrics to measure and track changes in breast tissue composition and density. To access a broad
range of densities in a limited patient population, we performed optical measurements on the contralateral normal
breast of patients before and during neoadjuvant chemotherapy (NAC). In this work, DOSI parameters, including
tissue hemoglobin, water, and lipid concentrations, were obtained and correlated with magnetic resonance
imaging (MRI)-measured fibroglandular tissue density. We evaluated how DOSI could be used to assess breast
density while gaining new insight into the impact of chemotherapy on breast tissue.
Methods: This was a retrospective study of 28 volunteers undergoing NAC treatment for breast cancer. Both 3.0-T
MRI and broadband DOSI (650 to 1,000 nm) were obtained from the contralateral normal breast before and during
NAC. Longitudinal DOSI measurements were used to calculate breast tissue concentrations of oxygenated and
deoxygenated hemoglobin, water, and lipid. These values were compared with MRI-measured fibroglandular
density before and during therapy.
Results: Water (r = 0.843; P < 0.001), deoxyhemoglobin (r = 0.785; P = 0.003), and lipid (r = -0.707; P = 0.010)
concentration measured with DOSI correlated strongly with MRI-measured density before therapy. Mean DOSI
parameters differed significantly between pre- and postmenopausal subjects at baseline (water, P < 0.001;
deoxyhemoglobin, P = 0.024; lipid, P = 0.006). During NAC treatment measured at about 90 days, significant reductions
were observed in oxyhemoglobin for pre- (-20.0%; 95% confidence interval (CI), -32.7 to -7.4) and postmenopausal
subjects (-20.1%; 95% CI, -31.4 to -8.8), and water concentration for premenopausal subjects (-11.9%; 95% CI, -17.1 to -6.7)
compared with baseline. Lipid increased slightly in premenopausal subjects (3.8%; 95% CI, 1.1 to 6.5), and water increased
slightly in postmenopausal subjects (4.4%; 95% CI, 0.1 to 8.6). Percentage change in water at the end of therapy
compared with baseline correlated strongly with percentage change in MRI-measured density (r = 0.864; P = 0.012).
Conclusions: DOSI functional measurements correlate with MRI fibroglandular density, both before therapy and
during NAC. Although from a limited patient dataset, these results suggest that DOSI may provide new functional
indices of density based on hemoglobin and water that could be used at the bedside to assess response to
therapy and evaluate disease risk.
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Introduction
Breast density, an assessment of the volume fraction of the
human breast that contains epithelial and connective tis-
sues, is a risk factor for breast cancer. Numerous studies
have shown that women with the highest density category
evaluated from mammography have fourfold to sixfold
increased cancer risk compared with women with lower
density [1]. In addition, the International Breast Cancer
Intervention Study (IBIS-I) primary chemoprevention
study, evaluating the selective estrogen-receptor modula-
tor (SERM) tamoxifen [2,3], revealed that only women
who exhibited >10% reduction in percentage mammo-
graphic density experienced the protective effect of tamox-
ifen in decreased cancer incidence [4]. Women in the
treated group who showed <10% decreased density had
exactly the same cancer rates compared with the control
group. Similar results were also recently found regarding
the use of tamoxifen and aromatase inhibitors in the adju-
vant setting [5]. These and related studies suggest that
breast tissue density, in addition to being a risk factor,
may also be a surrogate biomarker for monitoring, pre-
dicting, and optimizing individual response to hormonal
therapies. However, methods to measure breast density by
mammography or MRI have not been adopted for various
reasons, preventing the utilization of breast-density mea-
surements in the clinic to assess risk or predict outcome.
The only established criterion for assessing breast den-
sity is given by the Breast Imaging Reporting and Data
System (BI-RADS) [6]. That system defines four categories
for breast density, qualitatively based on the relative
amounts of fat and dense fibroglandular tissue in a mam-
mogram. Although the system is useful for evaluating the
probability that a tumor is obscured by dense tissue on a
mammogram, it is not suitable for quantifying or measur-
ing small changes in density. An alternative approach is to
quantify PMD by using computer-based image-analysis
techniques of mammograms [7-11]. Whereas it is possible
to quantify density from the image, a 2D radiograph pro-
jection is inherently limited in its ability to quantify longi-
tudinal density changes accurately [12]. The use of
ionizing radiation also limits the frequency of measure-
ments, making it unsuitable for monitoring adjuvant or
preventive chemotherapy. We and others have investigated
the use of MRI [12-19], which is a safe and quantitative
technique for measuring breast density and volume, but
its high cost precludes it from being applied for risk
assessment and screening in most women.
Optical-based imaging modalities are a promising
alternative to characterize breast density. Because of the
absorption and scattering properties of breast tissue,
near-infrared light (650 to 1,000 nm) is able to penetrate
several centimeters deep. Researchers have measured
breast tissue in transmission and reflectance geometries
by using continuous-wave spectroscopy, frequency-
domain, or time-domain techniques [20,21]. To corre-
late tissue optical measurements with breast density,
several groups have compared spectroscopic features or
measured tissue components (such as blood, water, and
lipid) with mammographic density. These optically mea-
sured parameters have been compared against breast
densities that have been qualitatively analyzed from
mammograms, classified into only three or four density
categories [22-28]. As mentioned earlier, this limits the
ability of the measurement to detect small density
changes. Promising work attempted to correlate mam-
mographic density with transillumination optical spec-
troscopy [29,30], but these studies did not quantify
tissue scattering and biochemical composition. This
makes it difficult to compare patient spectroscopic fea-
tures and to link functional changes with underlying
mechanisms of breast density.
We hypothesize that diffuse optical spectroscopic ima-
ging (DOSI) provides quantitative metrics to measure and
track changes in breast tissue composition and density.
DOSI provides a quantitative measure of tissue functional
components, allowing noninvasive imaging of breast tissue
composition and metabolism [31]. DOSI is capable of
measuring tissue concentrations (ct) of oxygenated hemo-
globin (ctO2Hb), deoxygenated hemoglobin (ctHHb),
water, and lipid. These measurements are directly related
to tissue metabolism and vascular characteristics. For
example, high levels of ctO2Hb are considered to be a sur-
rogate marker for elevated vascular supply and perfusion.
High levels of ctHHb reflect high oxygen consumption
and tissue metabolism due to cell proliferation and/or
poor vascular drainage. Total hemoglobin (ctTHb) corre-
sponds to the total blood volume in tissue and has been
validated as an index that corresponds to increased vascu-
lar density [32].
DOSI scanning is performed without compression or
injection of contrast agents by using a bedside hand-held
probe. Much of this work has been focused on determin-
ing functional changes in breast tumors during che-
motherapy, a topic that is now under investigation in an
American College of Radiology Imaging Networks
(ACRIN) multicenter clinical trial [33]. The DOSI techni-
que combines laser-based frequency-domain photon
migration with broadband near-infrared spectroscopy to
separate optical absorption and scattering over a broad
spectral range [20]. This results in a quantitative dataset of
tissue concentrations that can be compared longitudinally
in the same patient, or across different patients.
Our previous studies [34-36] showed that premenopau-
sal women tend to have greater water concentration than
do postmenopausal women, reflecting the high water
content of epithelial connective-tissue compartments.
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Similarly, premenopausal women have a higher hemoglo-
bin concentration (both ctHHb and ctO2Hb), because of
greater vascular demands of the glandular tissue, and a
lower lipid concentration. Based on these data, we expect
that breast density, which quantifies the abundance of hor-
monally controlled glandular tissue, exhibits a positive cor-
relation with water and ctTHb and a negative correlation
with lipid.
Because it is known that neoadjuvant chemotherapy
(NAC) affects the density and composition of normal
breast [37], in this study, we measured the contralateral
normal side of breast cancer patients before and during
NAC treatment with MRI and DOSI. We examined base-
line composition, comparing differences between pre- and
postmenopausal women. We analyzed DOSI parameters
for markers of breast density and metabolism. The correla-
tion between these results and fibroglandular tissue
density measured with MRI was examined to test the
hypothesis that DOSI can provide a quantitative measure
of breast density. We further hypothesize that, in addition
to providing an optical index of breast density, DOSI may
help provide insight into mechanisms of chemotherapy-
induced changes in breast metabolism.
Methods
Subject measurements
This study is a retrospective analysis conducted on a sub-
set of subjects with newly diagnosed, operative, primary
breast cancer measured with DOSI or DOSI+MRI during
their neoadjuvant chemotherapy treatment between 2007
and 2012. Subject demographics are shown in Table 1.
DOSI measurements were acquired at a minimum of 30
locations (taken in a rectangular grid pattern with 10-mm
spacing between measurement points) on a contralateral
breast not suggestive of malignancies at two or more time
points during the first 120 days of therapy (n = 28). The
DOSI+MRI cohort is a subset (n = 12) of subjects who
also received MRI imaging before NAC. Post-NAC MRI
images were available for nine subjects.
All subjects provided informed written consent and par-
ticipated in this study under clinical protocols approved by
the Institutional Review Board at the University of
California, Irvine (2002-2306, 2007-6084, and 2011-7812).
Exclusion criteria included pregnant women and women
who were younger than 21 years or older than 75 years.
All subjects were histologically diagnosed with invasive
carcinoma before neoadjuvant treatment.
DOSI measurement
A comprehensive description of the diffuse optical spec-
troscopic imaging (DOSI) system and underlying con-
cepts may be found elsewhere [38-40]. In brief, the
instrument combines frequency domain photon migra-
tion (FDPM) and continuous-wave near-infrared spectro-
scopy (CW-NIRS) measurements to determine the
optical scattering and absorption spectra (650 to 1,000
nm) of the measured tissue. The FDPM component con-
sists of six laser diode sources (660, 680, 780, 810, 830,
and 850 nm) that are sinusoidally intensity modulated
between 50 and 500 MHz. The relative amplitude and
phase of the detected signals compared with the source
are input into an analytic model of diffuse light transport
to determine tissue scattering and absorption coefficients
at these wavelengths. White-light illumination at each
measurement point is used for CW-NIRS spectroscopy.
The detected broadband reflectance spectra are fit and
scaled to the frequency-domain scattering and absorption
measurements to obtain full broadband absorption spec-
tra over the entire spectral range. Absolute tissue concen-
trations are calculated by using the Beer-Lambert law and
known extinction coefficient spectra of ctHHb, ctO2Hb,
water, and bulk lipid.
All subjects received NAC before surgical resection of
tumors and were measured with the DOSI system before
treatment (to establish a baseline measurement), and at
several time points throughout their treatment. Based on
our previous findings, baseline measurements were
obtained at least 10 days after diagnostic biopsies to mini-
mize their impact on DOSI scans [41]. Subjects were mea-
sured in a supine position. The DOSI probe was placed
against the breast tissue, and sequential measurements
were taken in a linear or rectangular grid pattern by using
10-mm spacing. Measurement regions on the normal
breast were taken to mirror the area of the underlying
tumor determined by ultrasound and palpation on the
ipsilateral breast. Total measurement time varied between
20 minutes and 1 hour per subject. Repeated DOSI scans
were shown previously to be relatively insensitive to
probe-contact pressure fluctuations, displaying less than
5% average variation in test/retest studies of human sub-
jects [42].
Mammographic density analysis
Each subject was characterized by a BI-RADS density
category. In this system, category I is described as fatty
breast tissue, II is scattered density, III is heterogeneously




DOSI cohort 47.4 ± 10.2 28
Premenopausal 40.8 ± 5.0 17
Postmenopausal 57.6 ± 7.2 11
DOSI+MRI cohort 43.6 ± 11.0 12
Premenopausal 38.l ± 5.3 9
Postmenopausal 60.0 ± 4.0 3
DOSI, diffuse optical spectroscopic imaging.
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dense, and IV is extremely dense. The categories were
compiled from prechemotherapy mammographic reports
documented by the subjects’ radiologists and were avail-
able for 20 of the 28 subjects. Of these, four subjects
were BI-RADS density II, eleven subjects were BI-RADS
III, and five subjects were BI-RADS IV.
MR imaging and breast-density analysis
MR imaging examinations were performed by using a
dedicated sensitivity-encoding-enabled bilateral four-chan-
nel breast coil with a 3.0-T system (Achieva; Philips Medi-
cal Systems, Best, The Netherlands) at time points before,
during, and after completion of NAC. The axial-view T1-
weighted images without fat suppression were used for the
analysis of breast density in this study. The images were
acquired by using a 2D turbo spin-echo pulse sequence
with TR, 800 milliseconds; TE, 8.6 milliseconds; flip angle,
90 degrees; matrix size, 480 × 480; FOV, 31 to 38 cm; and
slice thickness, 2 mm.
The breast and fibroglandular tissue segmentation was
performed by using a modified published method
[12,43,44]. Before the segmentation, the operator viewed
the whole axial T1W images dataset and determined the
superior and inferior boundaries of the breast (the begin-
ning and ending slices) by comparing the thickness of
breast fat with that of the body fat. The breast-segmenta-
tion procedures consisted of (a) an initial horizontal line
cut along the posterior margin of each individual subject’s
sternum to exclude thoracic region; (b) Applied Fuzzy-C-
Means (FCM) clustering and b-spline curve fitting
to obtain the breast-chest boundary; (c) a bias field-correc-
tion method based on nonparametric nonuniformity nor-
malization (N3), and an adaptive FCM algorithm [44] was
used to remove the strong intensity non-uniformity for
segmentation of fibroglandular tissue and fatty tissue; (d)
applied dynamic searching to exclude the skin along the
breast boundary; and (e) the standard FCM algorithm was
applied to classify all pixels on the image. The default set-
ting was to use a total of six clusters, three for fibroglandu-
lar tissue and three for fatty tissues. After completing the
segmentation processes in all image slices, the quantitative
breast volume, fibroglandular tissue volume, and the per-
centage density (calculated as the ratio of the fibroglandu-
lar tissue volume to the breast volume ×100%) were
calculated.
Neoadjuvant chemotherapy regimen
Most patients (n = 19) received a 12-cycle, once-a-week
course of a paclitaxel (either albumin-bound (nab-pacli-
taxel) or Cremophor-bound) and carboplatin. Other
patients received only doxorubicin+cyclophosphamiden
(AC therapy) (n = 2), or received additional AC therapy
either before (n = 4) or after (n = 2) paclitaxel+carboplatin.
The remaining patient received docetaxel+carboplatin for
six cycles, once every 3 weeks. Many patients also received
bevacizumab as part of their treatment (n = 15), and some




Summary statistics including mean and standard error
were calculated for the DOSI-measured parameters of
water, bulk lipid, ctO2Hb, ctHHb, ctTHb, oxygen satura-
tion (stO2), and tumor optical index (TOI) measured at
baseline and during NAC. TOI is a tissue optical index of
metabolism that provides contrast for metabolically active
tissue, developed for identifying tumors [45], and is given
by TOI = ctHHb × water/(% lipid). Subject measurements
during NAC were recorded as having occurred in one of
four intervals with interval midpoints 30 days (mean, 33.1;
range, 21 to 43/n = 16 pre-, n = 11 postmenopausal), 60
days (mean, 60.8; range, 55 to 69/n = 10 pre-, n = 7 post-
menopausal), 90 days (mean, 89.9; range, 78 to 104/n = 16
pre-, n = 9 postmenopausal), and 120 days (mean, 116.6;
range, 106 to 127/n = 6 pre-, n = 4 postmenopausal) from
the beginning of chemotherapy treatment.
Comparison of DOSI parameters between groups
The Mann-Whitney U test was applied to test whether
mean values for DOSI parameters differed significantly
between pre- and postmenopausal subjects. The Shapiro-
Wilkes test was applied to each DOSI parameter to test
the fit to a normal distribution within BI-RADS categories
II, III, and IV. Analysis of variance (ANOVA) was applied
to compare mean values among BI-RADS categories for
water, lipid concentration, ctO2Hb, ctHHb, ctTHb, and
scattering power. The nonparametric Kruskal-Wallis test
was applied to compare the distributions of stO2 and TOI
values among BI-RADS categories. For pairs of BI-RADS
categories (II versus III, II versus IV, and III versus IV),
the mean values for DOSI parameters were compared
with application of the Bonferroni-Holm method of
adjustment for multiple comparisons to maintain an
experiment-wise significance level of 0.05 for each DOSI
parameter.
Regression and correlation analyses
The linear relation between age and water concentration
measured at baseline was assessed with linear regression
analysis and the Pearson correlation coefficient. The influ-
ence of values obtained from individual patients was
assessed by examination of regression residuals and the
DFFITS statistic. In addition, the correlation between age
and change in water concentration at 90 days during NAC
was estimated with the Pearson correlation coefficient.
The correlation between DOSI parameters and MRI
fibroglandular density measured at baseline, as well as at
24 days and 82 days during NAC, was assessed with the
Pearson correlation coefficient. Similarly, the correlation
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between percentage change in DOSI parameters and
percentage change in MRI fibroglandular density at 82
days of NAC (that is, the end of NAC treatment) was
assessed with the Pearson correlation coefficient. A sig-
nificance level of 0.05 was used for assessment of esti-
mated correlations.
Generalized estimating equations
We applied a statistical method known as generalized
estimating equations (GEEs) to estimate and compare
the expected (mean) change from baseline for each spe-
cified DOSI parameter between pre- and postmenopau-
sal subjects. For example, the GEE method was used to
model the linear relation between the mean change in
breast-tissue water as a function of predictors including
menopausal status, measurement day after NAC, and
the interaction between menopausal status and measure-
ment day. Measurement day from the beginning of che-
motherapy was represented by a categorical variable
with four categories. In contrast to ordinary linear
regression, for which values measured in individual sub-
jects are assumed to be independent, the GEE method
takes in account the correlation between DOSI values
measured within individual subjects. For application of
the GEE, it is necessary to specify nature of the linear
relation between the mean value of the DOSI para-
meters and the predictors and between the mean and
variance of DOSI parameter values. The nature of the
within-subject correlations between DOSI measurements
must also be specified. In technical language, we speci-
fied a normal model with an identity-link function and
an exchangeable correlation structure. In brief, these
specifications indicated that the mean and variance of
the DOSI parameter are related through a normal distri-
bution and that the within-subject correlation between
repeated measurements of DOSI values was assumed to
be the same for each subject.
From the final GEE model for a given outcome, the
estimated percentage change from baseline was calcu-
lated and compared for both the pre- and the postme-
nopausal groups 30, 60, 90, and 120 days from the
beginning of chemotherapy. For analysis of each out-
come, the Bonferroni-Holm method of adjustment for
multiple comparisons was applied to maintain an
experiment-wise significance level of 0.05.
Results
For each patient examination, tissue concentrations of
ctO2Hb, ctHHb, water, and lipid were calculated at each
measurement point from the broadband absorption
spectra. These data were used to construct 2D maps by
using a linear interpolation between measurement
points, as shown in Figure 1. The areolar region pro-
vides significant contrast because of the high density of
fibroglandular tissue and its increased metabolic activity.
Optical absorption spectra of tissue in this region show
higher concentrations of hemoglobin and reduced lipid
content. For analysis, the average of DOSI measurement
parameters (chromophore concentrations and scattering
coefficients) was computed over the entire measurement
region but excluding the areola. Because the areolar
region is a concentrated region of fibroglandular tissue
not representative of the breast as a whole, it was
excluded from the DOSI average for this analysis; the
nipple also was excluded from MRI segmentation of
fibroglandular tissue. Identical measurement grids were
used for longitudinal analysis.
Baseline pre- and postmenopausal differences
Figure 2 shows the average optical absorption and scat-
tering spectra over all measurement points, excluding
the areola, for all premenopausal (n = 17) and postme-
nopausal (n = 11) subjects. Discernible differences are
present in both the absorption and scattering spectra
between premenopausal and postmenopausal women.
Premenopausal women exhibit higher concentrations of
hemoglobin, as evidenced by the overall higher absorp-
tion in the 670- to 850-nm range. Increased tissue water
concentration exists relative to lipids in premenopausal
women, as revealed by the large water-absorption peak
at 980 nm compared with the lipid peak at 930 nm.
Table 2 shows the absolute DOSI parameters for pre-
menopausal, postmenopausal, and all subjects at baseline
before beginning NAC treatment. In the absence of che-
motherapeutic intervention, pre- and postmenopausal
subjects exhibited statistically significant difference in
means for water (P < 0.001), lipid (P = 0.006), ctHHb (P
= 0.024), and the tissue optical index (TOI) (P = 0.003).
Postmenopausal women had a lower mean ctHHb and
mean water concentration at baseline than did premeno-
pausal women, and a higher mean lipid concentration.
Figure 3 shows maps of TOI for a typical premeno-
pausal and a postmenopausal subject. In both subjects,
the areolar region (indicated by the black line) exhibits
much higher TOI than does the surrounding tissue,
whereas the surrounding TOI tends to be higher in the
premenopausal subjects.
Because the mean tissue water concentration in the
normal breast was significantly different at baseline
between pre- and postmenopausal groups, the relation
between age and water concentration was examined to
explore these differences in more detail. For a subgroup
of 27 subjects (one patient was excluded as she pre-
viously underwent an oophorectomy, which caused pre-
mature menopause and confounds the effect of
hormones on breast density), water concentration at
baseline exhibited significant negative correlation (r =
-0.479; P = 0.011) with age (Figure 4). One subject with
extremely high breast density and corresponding water
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concentration (46.1%) exerted substantial influence on
the regression coefficients, as indicated by regression
diagnostics. Previous studies by our group and others
have shown that water concentration can vary dramati-
cally in premenopausal patients [36,46,47], perhaps
because of normal fluctuations caused by the menstrual
cycle [48], which may account for the outlier.
Relation between DOSI parameters and mammographic
density categories
The relations between DOSI parameters and mammo-
graphic-density categories, based on the four traditional
BI-RADS density categories, were assessed (Figure 5; all
data shown in Additional file 1, Table S1.). None of the
subjects measured was characterized as BI-RADS I. A sta-
tistically significant difference was found between BI-
RADS density categories III and IV for ctO2Hb, ctHHb,
ctTHb, and TOI. Additionally, a statistically significant dif-
ference was found between BI-RADS II and IV for water
and TOI. Mean lipid concentration tended to decrease
with increasing BI-RADS density category and approached
statistical significance. No significant difference in the
means of stO2 or scattering power was found.
Correlation between DOSI parameters and MRI breast
density
The correlations between measured DOSI parameters












Figure 1 Diffuse optical spectroscopic imaging (DOSI) measurement schematic. A two-dimensional map of functional properties is
generated by measuring broadband absorption and scattering spectra in a grid pattern. On the left is a grid (10 mm) in which each dot
represents a DOSI measurement point. The middle is a map of lipid concentration (actual breast data) generated from the measured spectra on
the right. Note that the areola region (A) has much less lipid concentration and overall higher optical absorption compared with the rest of the
breast (B) because of the higher concentration of water and hemoglobin in fibroglandular tissue.


























































Figure 2 Average absorption and scattering spectra measured at baseline for premenopausal (n = 17) and postmenopausal (n = 11)
subjects. First, the average value was computed for measurements within each subject, and then the means for the resulting spectra of all
subjects were computed. Error bars represent standard error.
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baseline and at various time points during NAC (Table 3).
At baseline, breast density calculated from MRI showed
stronger correlations with ctHHb (r = 0.785; P = 0.003),
water concentration (r = 0.843; P < 0.001), lipid (r =
-0.707; P = 0.010), and TOI (r = 0.891; P < 0.001) than
with other measures. Figure 6 illustrates the linear relation
between water and ctHHb with breast density. A statisti-
cally significant correlation with ctTHb (r = 0.597; P =
0.040) was also demonstrated. Figure 7 displays the MR
images and DOSI images at the beginning and end of
NAC for a 31-year-old premenopausal subject. This sub-
ject exhibited a significant reduction in breast density dur-
ing NAC, and, similarly, a significant reduction in water
concentration. However, when correlations between MRI
breast density and DOSI parameters were estimated at
time points near the conclusion of NAC treatment (that
is, about 82 days), nonsignificant correlations were found
(P > 0.05 for all DOSI parameters).
We also examined the correlation between percentage
change compared with baseline of the optical para-
meters and MRI fibroglandular density at about 82 days
(Table 4). A strong correlation of both change in water
(r = 0.864; P = 0.012) and TOI (r = 0.818; P = 0.025)
with MRI was found.
Variations in breast composition during NAC
Significant compositional changes of the normal breast
were observed during NAC in both pre- and postmeno-
pausal subjects with DOSI. GEE models that incorpo-
rated menopausal status and measurement day were
used to fit the outcomes of percentage change of DOSI
parameter from baseline. Because most NAC regimens
lasted 12 weeks, we show the GEE results at about 90
days from the beginning of NAC treatment (Figure 8).
The measured DOSI parameters at baseline before NAC
and at approximately 30, 60, 90, and 120 days after the
start of NAC are shown in Additional file 2, Table S1.
Both the premenopausal (-20.0%; 95% CI, -32.7 to -7.4)
and postmenopausal (-20.1%; 95% CI, -31.4 to -8.8)
groups exhibited statistically significant decreases in
ctO2Hb, whereas ctHHb stayed relatively flat (premeno-
pausal, -2.5%; 95% CI, -7.7 to 2.7; postmenopausal, 0.5%;
Table 2 Absolute tissue concentrations (mean ± standard error) measured in the normal breast at baseline
Water (%) Lipid (%) ctO2Hb (µM) ctHHb (µM) ctTHb (µM) stO2 (%) TOI
All
n = 28
21.4 ± 1.3 69.7 ± 1.3 18.0 ± 1.2 5.0 ± 0.2 23.0 ± 1.3 77.2 ± 0.9 1.7 ± 0.2
Pre
n = 17
24.4 ± 1.8c 67.0 ± 1.6b 18.9 ± 1.7 5.3 ± 0.2a 24.2 ± 1.9 76.8 ± 1.1 2.1 ± 0.3b
Post
n = 11
16.6 ± 0.7c 74.0 ± 1.4b 16.6 ± 1.5 4.5 ± 0.2a 21.1 ± 1.6 77.7 ± 1.7 1.0 ± 0.1b
Data are shown for all patients, and for the premenopausal (pre) and postmenopausal (post) subgroups. ctO2Hb, oxyhemoglobin concentration; ctHHb,
deoxyhemoglobin concentration; ctTHb, total hemoglobin concentration; stO2, tissue oxygen saturation; TOI, tissue optical index.
a,b,cA statistically significant


















43 y/o pre-menopause 56 y/o post-menopause
Figure 3 Typical maps of tissue optical index (TOI) in the breast of a premenopausal and postmenopausal subject at baseline. The
outer limit of the areolar region is indicated by the black line. Tick-mark separation equals 1 cm. ctHHb, deoxyhemoglobin concentration.
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Figure 4 Breast-tissue water concentration at baseline decreased with age (r = -0.479; P = 0.011). Data shown are for 27 pre- and
postmenopausal subjects (one patient was excluded because she previously underwent an oophorectomy, confounding the effect of hormones
on breast density).



























































Figure 5 The mean value of measured diffuse optical spectroscopic imaging parameters, separated by the Breast Imaging-Reporting
and Data System (BI-RADS) density category. A statistically significant difference (*) was found between BI-RADS density categories III and IV
for oxyhemoglobin (ctO2Hb), deoxyhemoglobin (ctHHb), total hemoglobin (ctTHb), and tissue optical index (TOI). Additionally, a statistically
significant difference was found between BI-RADS II and IV for water and TOI. Error bars represent standard error.
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95% CI, -5.3 to 6.3), yielding a reduction of ctTHb. Bulk
lipids also remained relatively flat during NAC for both
pre- (3.8%; 95% CI, 1.1 to 6.5) and postmenopausal
(-0.4%; 95% CI, -3.4 to 2.6) groups. The stO2 was nearly
identical between the two groups at baseline, and both
decreased in a similar manner during NAC (premeno-
pausal, -6.9%; 95% CI, -11.5 to -2.3; postmenopausal,
-7.4%; 95% CI, -14.7 to 0.0). Scattering amplitude and
power did not change appreciably during NAC or
between groups (data not shown).
Trends during NAC were similar in both menopause
groups for all DOSI parameters except water (ctO2Hb,
shown in Figure 9A), which exhibited a percentage
change that was statistically different between menopause
groups at 90 days. Figure 9B shows that the premenopau-
sal group incurred a steady decrease in tissue water dur-
ing NAC, whereas breast-tissue water concentration in
the postmenopausal group remained flat. After 90 days of
NAC, premenopausal subjects exhibited an estimated
-11.9% (95% CI, -17.1 to -6.7) reduction in breast-tissue
water concentration, whereas postmenopausal subjects
showed an estimated increase of 4.4% (95% CI, 0.1 to
8.6). The percentage change in water after 90 days of che-
motherapy was correlated with age (Figure 9C; r = 0.745;
P < 0.001), providing further evidence that the effect of
NAC on water concentration is stronger in younger, pre-
menopausal subjects.
Discussion
Breast density is a strong independent risk factor for breast
cancer and may also have a role in the risk of recurrence.
Optical imaging is a low-cost imaging modality that shows
promise for assessing breast density in the clinic without
the use of ionizing radiation. Because optical imaging
Table 3 Correlation between diffuse optical spectroscopic imaging parameters and fibroglandular density measured
with magnetic resonance imaging for subjects at baseline and at time points during chemotherapy
Baseline (n = 12) ~25 days (n = 10)
Mean, 24.8 ± 5.5
~82 days (n = 7)
Mean, 82.4 ± 11.9
R P R P r P
Water 0.843 <0.001 0.675 0.032 0.405 0.367
Lipid -0.707 0.010 -0.462 0.179 -0.018 0.970
ctO2Hb 0.557 0.060 0.647 0.043 0.464 0.294
ctHHb 0.785 0.003 0.399 0.253 0.705 0.077
ctTHb 0.597 0.040 0.644 0.045 0.599 0.155
stO2 0.196 0.543 0.240 0.505 0.012 0.979
TOI 0.891 <0.001 0.541 0.107 0.593 0.160
Scat. power 0.205 0.523 0.143 0.694 0.265 0.566
Bold values indicate statistical significance at the 0.05 level. ctO2Hb, oxyhemoglobin concentration; ctHHb, deoxyhemoglobin concentration; ctTHb, total
hemoglobin concentration; stO2, tissue oxygen saturation; TOI, tissue optical index; Scat. power, optical scattering power.
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Water (%) - DOSI
Figure 6 Correlation between optically measured deoxyhemoglobin (ctHHb) and water, with fibroglandular density measured with
magnetic resonance imaging (MRI). Data are for 12 subjects (all subjects for whom we had available corresponding data) at baseline before
chemotherapy (nine pre- and three postmenopausal). The fitted linear regression line is superimposed on the graph.
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measures functional characteristics of tissue, it also yields
additional information that complements breast-density-
assessment techniques using MRI and mammography,
which are based primarily on structure. This additional
information may help to elucidate the origin of breast den-
sity and to clarify causes of both natural and treatment-
induced changes of breast density. By understanding the
factors that modulate breast density and the source of its
contrast in imaging, we will be able to apply the parameter
better in risk assessment.
Conflicting information exists in the literature correlat-
ing optically measured tissue components with breast den-
sity. Most agree that increasing density correlates with
increasing water concentration and ctTHb. However, con-
flicting data are found on other measures, including bulk
lipid, which has found to be negatively correlated with
density [27], or not at all [24]. Oxygen saturation (the
fraction of ctO2Hb to ctTHb, or stO2) has been shown to
be reduced in dense tissue [25], whereas others do not
find a significant correlation [24,27]. In addition, Taroni
et al. [27] included collagen as a basis chromophore and
found that it is strongly associated with BI-RADS cate-
gories II-IV. Optical scattering is also expected to increase
with greater breast density because of the underlying fibro-
glandular structures, and some studies have indeed shown
this [25,27]. It is possible that these disagreements are due
to the broad classification of density categories, to the lim-
ited ability of the applied optical modalities to quantify tis-
sue components accurately, or to some combination of
the two.
In this study, we found that water, ctO2Hb, ctHHb,
ctTHb, and TOI are associated with the BI-RADS density
category, whereas lipid tended to decrease with increasing















Figure 7 Corresponding magnetic resonance imaging (MRI) and diffuse optical spectroscopic imaging (DOSI). Images were taken at
baseline and end of neoadjuvant chemotherapy in the contralateral normal breast of a premenopausal patient. The yellow outlines in the MRI
images depict the result of the segmentation algorithm for fibroglandular tissue in the shown slices. The DOSI maps depict measured
parameters as a function of position (tick mark separation equals 1 cm). The illustrated maps are from an 8- × 6-cm area from the upper-inner
region of the left breast. The areolar region has more water, outlined by the semicircle. The decreased density after chemotherapy is clearly
visible in both MRI and DOSI. MRI shows 30.4% reduction in fibroglandular tissue volume, and DOSI shows 24.4% reduction in tissue water.
ctHHb, deoxyhemoglobin concentration; TOI, tissue optical index.
Table 4 Correlation between percentage change in optical parameters and percentage change in fibroglandular









Scat. power 0.195 0.675
Data are for the seven subjects measured at approximately 82 days of chemotherapy (five pre- and two postmenopausal). Bold values indicate statistical
significance at the 0.05 significance level. ctO2Hb, oxyhemoglobin concentration; ctHHb, deoxyhemoglobin concentration; ctTHb, total hemoglobin concentration;
stO2, tissue oxygen saturation; TOI, tissue optical index; Scat. power, optical scattering power.
O’Sullivan et al. Breast Cancer Research 2013, 15:R14
http://breast-cancer-research.com/content/15/1/R14
Page 10 of 15
mean differences in hemoglobin were found between BI-
RADS density categories III and IV, but not category II
and IV. This contradiction is likely due to the small sam-
ple size (n = 4 with BI-RADS II) and the limitations of a
broad density-classification scheme. We expect lipid to be
significantly associated with the BI-RADS category in a
larger sample size. No association was discovered between
stO2 or scattering power with BI-RADS density.
Several DOSI parameters were strongly correlated with
MRI fibroglandular breast density measured at baseline,
including tissue water, lipid, and ctHHb concentrations.
No significant correlation was noted between density and
scattering parameters or stO2. This significant correlation
with water is likely because fibroglandular tissue has about
30% higher water content than does adipose tissue [24].
These observations are in general agreement with the find-
ings of other groups, with the addition that here we show,
for the first time, that a quantitative measure of water can
be compared longitudinally and between patients. Because
DOSI is a measurement of chromophore concentration
throughout the probed tissue volume, the increased water
may also be due to the increased vascular supply required
by the dense tissue. Furthermore, we demonstrated a
strong baseline correlation between ctHHb and breast
density, reflecting the increased rate of metabolism in
fibroglandular breast tissue. Because metabolism is
strongly captured in the tissue optical index (TOI), this
metric was also shown to be a good predictor of breast
density. Finally, greater hemoglobin concentrations were
observed in patients with dense breasts, suggesting greater
vascular density in these subjects, and lower lipid concen-
trations, as would be expected by the greater volume frac-
tion of fibroglandular tissue compared to adipose.
At baseline, we observed statistically significant differ-
ences in the breast composition and indicators of metabo-
lism for premenopausal and postmenopausal groups,
confirming previous studies [47]. Increased mean ctHHb
and mean water concentrations were found, as well as
decreased mean bulk lipid concentration in the breasts of
premenopausal subjects, compared with those of postme-
nopausal subjects. This is all consistent with increased cell
proliferation and metabolic activity in the denser breast
tissue of younger premenopausal women.
Significant changes in optical markers for vascular den-
sity and supply (ctO2Hb and water) were observed during
NAC treatment. A significant decrease in ctO2Hb was
observed in both premenopausal and postmenopausal
groups. The steady reduction of ctO2Hb without a corre-
sponding decrease in ctHHb suggests that NAC agents act
directly on the breast tissue, perhaps by causing a reduc-
tion of perfusion. This may be caused by chemotherapy-
induced vascular damage and may contribute to the
reduction of breast density. In contrast, only premenopau-
sal subjects experienced a significant loss of water in their
breast tissue during NAC. This trend better matches the
observed effect of NAC on MRI-measured breast density
wherein premenopausal subjects experience a greater loss
[37]. Even though the absolute DOSI parameters were not





























Figure 8 Percentage change in water, deoxyhemoglobin (ctHHb), oxyhemoglobin (ctO2Hb), lipid, and tissue oxygen saturation (stO2) at 90
days of chemotherapy treatment compared with baseline. Based on longitudinal generalized estimating equation models, a statistically
significant difference in water (*) was found between premenopausal and postmenopausal groups. Error bars represent standard error.
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# Days since first chemotherapy infusion
Premenopausal (N=17)
Postmenopausal (N=11)
Figure 9 Optically measured changes over time during chemotherapy. (A) Oxyhemoglobin concentration (ctO2Hb) decreased during
chemotherapy (90 days) for both groups of patients. (B) Water concentration decreased in premenopausal patients during chemotherapy and
remained relatively unchanged in postmenopausal patients. (C) The reduction of water observed after 90 days of chemotherapy was associated
with age (r = 0.745; P < 0.001), with younger subjects exhibiting a greater reduction. Data shown are for 24 pre- and postmenopausal subjects in
whom we had measurement data at 90 days (one patient was excluded because she previously underwent an oophorectomy, confounding the
effect of hormones on breast density). The fitted linear regression line is superimposed on the graph.
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significantly correlated with MRI measurements at the end
of NAC, the percentage change in water and TOI at the
end of treatment compared with baseline did show strong
correlation with the percentage change in fibroglandular
breast density over the same time.
These NAC-induced changes could potentially have
been caused by direct antiproliferative effects of che-
motherapy, or by the indirect effect of ovarian suppression
and subsequent hormone-level reductions [37]. Cytoxic
chemotherapeutic agents are known to cause suppression
of ovarian function and amenorrhea, whereas ovarian-
secreted hormones (estrogen and progesterone) are
known to increase breast density [49-51]. The greater
reduction in breast-tissue water in younger, premenopau-
sal subjects suggests that their chemo-reduced ovarian
hormone levels may have a role in reducing breast-tissue
density. Consequently, the change in ctO2Hb also suggests
a hormone-independent mechanism. The enhanced
breast-density reduction in premenopausal subjects could
also be because breast tissue naturally becomes less dense
with age [52,53]. Evidence suggests that this is also a hor-
monal effect [49-51]; however, it is due to natural aging
and not induced by the chemotherapy. This is reflected in
the reduced baseline water concentration of older subjects.
If less fibroglandular tissue is present in the breasts of the
older women, then it is possible that NAC may not be
able to cause a significant change in breast density (that is,
it has already been reduced to minimum). This compli-
cates the ability to separate the relative importance of che-
motherapy as a direct or indirect modulator of breast
density.
We note that relatively little change over time was
observed in mean DOSI-measured bulk lipid in both
groups of patients undergoing NAC. This suggests that
the rapid changes in breast density induced by NAC
occur because of the reduction of the fibroglandular tis-
sue rather than by increases or replacement by bulk lipid.
This study is limited because it is a retrospective study
and includes a small number of subjects, especially those
with matched DOSI and MRI measurements. Therefore,
the reported correlations should be interpreted with cau-
tion, and they point to the need for further studies.
Furthermore, DOSI measurements did not sample the
entire breast volume. Recent data have shown, however,
that density-related measurements from a spatially limited
optical sampling on the breast are strongly associated with
the BI-RADS category [28]. Multiple therapy regimens
were included in the analysis, and it is likely that the
underlying changes in breast density vary, based on the
specific chemotherapy drugs given. Future work stratifying
DOSI changes by treatment type and outcome in a larger
population may provide insight into mechanisms of these
changes, as well as patient response to therapy. Addition-
ally, timing of the subjects’ menstrual cycles was not
accounted for, which can cause variations in breast den-
sity, nor their pregnancy history. Nonetheless, the ability
to identify significant correlations over several years of
optical measurements speaks to the strength of the DOSI
method as a promising quantitative tool.
Conclusions
In conclusion, this is the first study to confirm that optical
imaging can detect significant compositional and func-
tional changes in the contralateral normal breast before
and during chemotherapy, and these changes are corre-
lated with MRI anatomic measurements of breast density.
Density is a strong independent risk factor for breast can-
cer, and the ability to quantify it could be valuable input
to breast cancer risk models. Imaging biomarkers could be
used to provide individualized treatment and predict
response as well as risk of recurrence in breast cancer
patients. Together with tissue analysis, DOSI may provide
insight into the underlying biologic origin of density and
improve our understanding of the hormonal and che-
motherapy effects. Prospective studies must be performed
to understand further the correlation of parameters mea-
sured with DOSI and MRI breast-imaging modalities. If
validated, DOSI may provide an alternative approach to
predict cancer risk as well as to monitor the protective
effects of cancer therapies.
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